MedPath

A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation

Phase 2
Recruiting
Conditions
Neoplasms
Vulvar Cancer
Anal Cancer
Breast Cancer
Cancer Suspect
Hiv
HNSCC
Cervical Cancer
Interventions
Other: Potlako intervention
Other: Enhanced care
Registration Number
NCT04141449
Lead Sponsor
Brigham and Women's Hospital
Brief Summary

This study evaluates whether the Potlako+ intervention of community education, clinical provider support, and patient navigation can improve access to cancer case for patients presenting with symptoms of cancer. Half of communities will receive the Potlako+ intervention, while the other communities will continue to receive standard programs.

Detailed Description

The Potlako+ trial is a pair-matched, community-randomized study involving 20 rural and peri-urban communities in Botswana (population \~190,100 with \~100,000 30 years or older). Communities will be randomized 1:1 to the Potlako+ intervention versus standard care. The goal of the intervention is to identify individuals with symptoms/signs suggestive of cancer and expedite diagnosis (and treatment).

The trial includes a community education component focused on cancer awareness and importance of early diagnosis and a patient navigation component that aims to expedite the diagnostic evaluation. Community education will be directed at approximately 50,000 community residents (30 years and older). We anticipate approximately 1500 cancer suspects will be identified by their clinic providers.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
1500
Inclusion Criteria
  • Botswana citizen * Age 30 years or older * engaged in longitudinal care for chronic health problem * resident of study community 2.
Exclusion Criteria
  • Involuntary incarceration * Educational messaging could interfere with clinical management or increase distress in the opinion or clinic or research staff
  1. Cancer suspects

    1. Inclusion Criteria:

      • Botswana citizen
      • Age 30 years or older
      • resident of study community
      • Recorded as a cancer suspect by clinic staff
    2. Exclusion Criteria

      • Involuntary incarceration
      • Unable or unwilling to provide confirmation of informed consent
      • Already engaged in oncology care

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Potlako interventionPotlako intervention* Provider oncology training focused on detection of cancer symptoms/signs and performance of appropriate diagnostic evaluation * Community-led cancer symptom awareness campaign to educate residents on methods and importance of early detection of cancer * Support/counselling call after initial clinician recognition that patient requires evaluation for possible cancer. * Cross-sectional community-facing activities partnered with longitudinal clinic-based targeted educational program * Remote phone/SMS-based cancer suspect navigation program to support and expedite evaluation for symptoms/signs of possible cancer.
Enhanced CareEnhanced care* Provider oncology training focused on detection of cancer symptoms/signs and performance of appropriate diagnostic evaluation. * Support/counselling call after initial clinician recognition that patient requires evaluation for possible cancer.
Primary Outcome Measures
NameTimeMethod
Duration of combined Appraisal and Help-seeking intervalsBaseline

Number of days from patient symptom awareness to first clinic visit, among patients with moderate or high probability of cancer

Duration of Pre-Treatment intervalFrom date of cancer diagnosis to date of cancer treatment up to 365 days

Number of days from cancer diagnosis to cancer treatment

Proportion of patients treated with limited stage cancerFrom date of cancer diagnosis to date of cancer treatment up to 365 days

Among patients with confirmed cancer, proportion treated with stage I/II disease

Duration of Diagnostic intervalFrom date of first clinic visit to date of cancer diagnosis or diagnosis excluding cancer, up to 365 days

Number of days from first clinic visit to cancer diagnosis or diagnosis excluding cancer, among patients with moderate or high probability of cancer

Incidence of curative-intent treatmentFrom intervention start up to trial end at 1825 days

Cumulative incidence (cases per standardized population) of initiation of curative-intent cancer treatment

Secondary Outcome Measures
NameTimeMethod
Incident low probability cancer syndromesBaseline

Cumulative incidence (cases per standardized population) of presentation with low probability cancer syndromes

Incident invasive procedures in cancer suspectsFrom intervention start up to trial end at 1825 days

Cumulative incidence (cases per standardized population) of presentation with low, moderate, or high probability cancer syndromes

Patients treated for cancerFrom date of cancer diagnosis to date of cancer treatment up to 365 days

Among patients with confirmed cancer, proportion of cancer cases receiving any cancer-specific therapy

Final diagnosis within 8 weeksFrom date of first clinic visit to date of cancer diagnosis or diagnosis excluding cancer, up to 56 days

Among patients with moderate to high probability cancer symptoms, proportion with cancer diagnosis or exclusion of cancer diagnosis within 8 weeks of initial clinic visit

Cancer presenting as emergencyFrom date of cancer diagnosis to date of cancer treatment up to 7 days

Among patients with confirmed cancer, proportion of cancer cases presenting as emergency (inpatient admission or death within 1 week of presentation with symptom).

Trial Locations

Locations (1)

Botswana Harvard AIDS Institute

🇧🇼

Gaborone, Botswana

© Copyright 2025. All Rights Reserved by MedPath